Skip to main content

OneMedNet Expands Into $1.5B Healthcare Data Annotation Market With MedCase

MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with Medcase, a worldwide network of healthcare professionals focused on medical data annotation. This collaboration establishes a new market entry point for OneMedNet and opens a high-growth revenue channel in the healthcare AI ecosystem.

Strategic Expansion into Healthcare Data Annotation

The global healthcare data annotation market, valued at $1.5 billion in 2025 and projected to be $2.8 billion by 2030, has entered a pivotal growth phase1. Scale AI’s $14.8B investment from Meta has disrupted the industry, triggering an exodus of major clients concerned about competitive intelligence. This shift has created an immediate opportunity for specialized providers focused solely on healthcare—where regulatory compliance, domain expertise, and trust are paramount. With Medcase’s 15,000+ healthcare professionals delivering world-class annotation services, OneMedNet gains a strategic foothold in this fast-growing market, expanding beyond RWD into a complementary and recurring revenue stream.

Leveraging OneMedNet’s Proprietary iRWD™ Platform

In turn, Medcase will leverage OneMedNet’s nationwide provider network and iRWD™ platform to give its clients access to regulatory-grade, de-identified Real-World Data across clinical data including imaging, and EHR data. This combination of high-quality RWD with expert annotation represents a unique competitive advantage for both companies—one that cannot be easily replicated by generalist data players.

High-Growth Market Opportunity

  • 58% YoY headcount growth among healthcare-specific data curation providers underscores the market’s acceleration2.
  • Domain-specific, proprietary data is increasingly the critical differentiator in AI model development.
  • Healthcare remains the largest and most regulated opportunity in AI training data, with rising demand for privacy-compliant, longitudinal datasets2.

“This partnership positions OneMedNet at the center of the healthcare data value chain,” said Aaron Green, CEO & President of OneMedNet. “By combining our iRWD™ platform with Medcase’s annotation expertise, we are extremely well positioned to serve a large unmet market need, unlocking new growth channels that directly strengthen our long-term revenue trajectory.”

“The demand for specialized healthcare annotation is accelerating faster than ever,” said Niv Shochat, CEO of Medcase. “By aligning with OneMedNet, we can now offer our clients access to unparalleled Real-World Data, creating a defensible position in one of AI’s most valuable verticals.”

Positioned for Scale

The global data annotation industry spans multiple enterprise sectors—including automotive, retail, and fintech—but healthcare stands apart as the fastest-growing and most defensible vertical. Together, OneMedNet and Medcase are positioned to deliver recurring, high-margin revenue streams by meeting the unique requirements of healthcare AI developers, pharmaceutical companies, and medical technology leaders.

  1. Healthcare Data Collection & Labeling Market Size 2025-2030. (n.d.). – https://www.360iresearch.com/library/intelligence/healthcare-data-collection-labeling
  2. CB Insights – https://www.cbinsights.com/esp/enterprise-tech/bi-&-operational-intelligence/data-annotation

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.

About MedCase

Medcase Health is a global leader in clinician-led medical data enrichment and healthcare AI services. We connect AI developers, pharmaceutical companies, and medtech leaders with verified health care professionals who deliver precise, specialty-specific labeling across imaging, medical device data, electronic health records and more. Beyond annotation, we provide expert-led audits, FDA-compliant reader studies, and quality oversight to ensure regulatory-grade datasets.

Through collaborations with some of the world’s most prominent technology companies and fast-growing health AI startups, we combine clinical expertise with advanced data enrichment platforms to accelerate model training, improve accuracy, and reduce time to market. With more than 15,000 clinicians worldwide, Medcase enables organizations to scale quickly, meet complex regulatory requirements, and power the next generation of healthcare innovation.

https://www.medcase.health/

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations..

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.